Pharma BD Deal Intelligence
A $25M upfront, $490M+ milestone licensing deal that hands Genentech exclusive global rights to Astex's early-stage breast-cancer small-molecule discovery program. The deep discount to headline value and undisclosed target reflect a preclinical-stage bet, not a validated asset.
Early-stage breast-cancer in-license, milestone-weighted
Full analysis, sources & comparables →Astex grants Genentech an exclusive worldwide license to its FBDD breast-cancer program; >$490M upfront+milestones plus tiered royalties.
Genentech signs breast-cancer discovery deal with Otsuka's Astex worth up to ~$515M in upfront and milestones.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Astex Pharmaceuticals (an Otsuka company) announced on July 6, 2026 an exclusive, worldwide research collaboration and license agreement with Genentech (a member of the Roche Group) to develop small-molecule inhibitors of a key cell-cycle-dependent regulator as potential breast-cancer therapies. Astex receives USD 25 million upfront and is eligible for preclinical, clinical, regulatory and sales milestones totaling more than USD 490 million, plus tiered royalties. Astex grants Genentech an exclusive license to compounds from its existing breast-cancer discovery program (originating from work with Newcastle University and Cancer Research Horizons); Genentech takes sole responsibility for preclinical/clinical development and global commercialization.
Breast cancer is the most common cancer in women worldwide. The Astex-Genentech collaboration targets a key cell-cycle-dependent regulator with selective small molecules, aiming to add a differentiated mechanism to breast-cancer treatment. Lead compounds are at the discovery/preclinical stage; the specific target was not disclosed.
Genentech gains exclusive worldwide license to Astex's cell-cycle inhibitor breast-cancer program: $25M upfront + >$490M milestones + royalties.
Small upfront for an early breast-cancer discovery asset; Genentech carries all development. Milestone-weighted with real but early upside.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genentech, Inc. (Roche Group) / Astex Pharmaceuticals (this deal) | 2026 | $490M | 58 |
| Genentech, Inc. (Roche Group) / Duality Biologics (Suzhou) Co. Ltd. | 2026 | $1.0B | 100 |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2026 | $2.3B | 100 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
| Genentech, Inc. (Roche Group) / Affimed N.V. | 2018 | $5.1B | — |
| Genentech, Inc. (Roche Group) / Hanmi Pharmaceutical Co. Ltd. | 2016 | $910M | — |
| Genentech, Inc. (Roche Group) / Regor Pharmaceuticals Inc. | 2024 | $850M | — |
← Browse all deals · How we score deals
More: 2026 deals · Genentech, Inc. (Roche Group) deals · Oncology deals